# Efficacy and Safety in Imlifidase Desensitized Kidney Tx Patients, Including Two Non-Comparative Reference Cohorts

> **NCT05369975** · PHASE3 · COMPLETED · sponsor: **Hansa Biopharma AB** · enrollment: 113 (actual)

## Conditions studied

- Kidney Transplantation in Highly Sensitized Patients

## Interventions

- **DRUG:** Imlifidase
- **OTHER:** Normal Transplantation Routine

## Key facts

- **NCT ID:** NCT05369975
- **Lead sponsor:** Hansa Biopharma AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-19
- **Primary completion:** 2026-04-21
- **Final completion:** 2026-04-21
- **Target enrollment:** 113 (ACTUAL)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05369975

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05369975, "Efficacy and Safety in Imlifidase Desensitized Kidney Tx Patients, Including Two Non-Comparative Reference Cohorts". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05369975. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*